What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions?

Daniel Sargent

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The need to practice evidence-based medicine is the current prevailing paradigm within the medical community. Evidence to guide practice can and should come from a variety of sources, including clinical trials, observational studies, and meta-analyses of both or either. This paper discusses the relative strengths and weaknesses of data that arise from these various sources. The different types of evidence required to demonstrate "efficacy" versus "effectiveness," a critical and often overlooked distinction, are discussed. In the genomic age, in which targeted therapies with or without specific biomarkers are emerging in cancer care, new approaches are necessary to generate the evidence required for decision making.

Original languageEnglish (US)
Pages (from-to)19-23
Number of pages5
JournalThe oncologist
Volume15 Suppl 1
StatePublished - 2010

Fingerprint

Evidence-Based Medicine
Observational Studies
Meta-Analysis
Decision Making
Biomarkers
Clinical Trials
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions? / Sargent, Daniel.

In: The oncologist, Vol. 15 Suppl 1, 2010, p. 19-23.

Research output: Contribution to journalArticle

@article{e8d0976b5cb742c39c381f17b614407d,
title = "What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions?",
abstract = "The need to practice evidence-based medicine is the current prevailing paradigm within the medical community. Evidence to guide practice can and should come from a variety of sources, including clinical trials, observational studies, and meta-analyses of both or either. This paper discusses the relative strengths and weaknesses of data that arise from these various sources. The different types of evidence required to demonstrate {"}efficacy{"} versus {"}effectiveness,{"} a critical and often overlooked distinction, are discussed. In the genomic age, in which targeted therapies with or without specific biomarkers are emerging in cancer care, new approaches are necessary to generate the evidence required for decision making.",
author = "Daniel Sargent",
year = "2010",
language = "English (US)",
volume = "15 Suppl 1",
pages = "19--23",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",

}

TY - JOUR

T1 - What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions?

AU - Sargent, Daniel

PY - 2010

Y1 - 2010

N2 - The need to practice evidence-based medicine is the current prevailing paradigm within the medical community. Evidence to guide practice can and should come from a variety of sources, including clinical trials, observational studies, and meta-analyses of both or either. This paper discusses the relative strengths and weaknesses of data that arise from these various sources. The different types of evidence required to demonstrate "efficacy" versus "effectiveness," a critical and often overlooked distinction, are discussed. In the genomic age, in which targeted therapies with or without specific biomarkers are emerging in cancer care, new approaches are necessary to generate the evidence required for decision making.

AB - The need to practice evidence-based medicine is the current prevailing paradigm within the medical community. Evidence to guide practice can and should come from a variety of sources, including clinical trials, observational studies, and meta-analyses of both or either. This paper discusses the relative strengths and weaknesses of data that arise from these various sources. The different types of evidence required to demonstrate "efficacy" versus "effectiveness," a critical and often overlooked distinction, are discussed. In the genomic age, in which targeted therapies with or without specific biomarkers are emerging in cancer care, new approaches are necessary to generate the evidence required for decision making.

UR - http://www.scopus.com/inward/record.url?scp=77954634393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954634393&partnerID=8YFLogxK

M3 - Article

C2 - 20237213

AN - SCOPUS:77954634393

VL - 15 Suppl 1

SP - 19

EP - 23

JO - Oncologist

JF - Oncologist

SN - 1083-7159

ER -